scholarly journals Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang

2013 ◽  
Vol 12 (1) ◽  
pp. 149 ◽  
Author(s):  
Xiayizha Kamali ◽  
Muhuyati Wulasihan ◽  
Yu-Chun Yang ◽  
Wu-Hong Lu ◽  
Zhi-Qiang Liu ◽  
...  
2021 ◽  
Vol 80 (3) ◽  
pp. 1329-1337
Author(s):  
Jure Mur ◽  
Daniel L. McCartney ◽  
Daniel I. Chasman ◽  
Peter M. Visscher ◽  
Graciela Muniz-Terrera ◽  
...  

Background: The genetic variant rs9923231 (VKORC1) is associated with differences in the coagulation of blood and consequentially with sensitivity to the drug warfarin. Variation in VKORC1 has been linked in a gene-based test to dementia/Alzheimer’s disease in the parents of participants, with suggestive evidence for an association for rs9923231 (p = 1.8×10–7), which was included in the genome-wide significant KAT8 locus. Objective: Our study aimed to investigate whether the relationship between rs9923231 and dementia persists only for certain dementia sub-types, and if those taking warfarin are at greater risk. Methods: We used logistic regression and data from 238,195 participants from UK Biobank to examine the relationship between VKORC1, risk of dementia, and the interplay with warfarin use. Results: Parental history of dementia, APOE variant, atrial fibrillation, diabetes, hypertension, and hypercholesterolemia all had strong associations with vascular dementia (p < 4.6×10–6). The T-allele in rs9923231 was linked to a lower warfarin dose (βperT - allele = –0.29, p < 2×10–16) and risk of vascular dementia (OR = 1.17, p = 0.010), but not other dementia sub-types. However, the risk of vascular dementia was not affected by warfarin use in carriers of the T-allele. Conclusion: Our study reports for the first time an association between rs9923231 and vascular dementia, but further research is warranted to explore potential mechanisms and specify the relationship between rs9923231 and features of vascular dementia.


Author(s):  
Sevasti-Maria Chaldoupi ◽  
Sabita S. Soedamah-Muthu ◽  
Jakub Regieli ◽  
Christian van de Werf ◽  
Marcel Nelen ◽  
...  

2014 ◽  
Vol 452 (3) ◽  
pp. 303-307 ◽  
Author(s):  
Ling Bai ◽  
Zhiqiang Liu ◽  
Maerjiaen Bakeyi ◽  
Wuhong Lu ◽  
Pengyi He ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (25) ◽  
pp. e7253 ◽  
Author(s):  
Yu-Feng Jiang ◽  
Min Chen ◽  
Nan-Nan Zhang ◽  
Hua-Jia Yang ◽  
Lang-Biao Xu ◽  
...  

2010 ◽  
Vol 14 (2) ◽  
pp. 249-253 ◽  
Author(s):  
Svetlana Nicoulina ◽  
Vladimir Shulman ◽  
Pavel Shesternya ◽  
Anna Chernova ◽  
Alla Salmina ◽  
...  

2019 ◽  
Author(s):  
Shan Zou ◽  
Lishan Wu ◽  
Zeliang Chen ◽  
Hongxiao Li ◽  
Hongjuan Chen ◽  
...  

Abstract Background: Numerous studies have demonstrated that patients with non-O blood groups have higher risk for venous thromboembolism than those with O blood group. However, it has remained unknown about the effect of ABO blood groups on warfarin dose requirements in patients receiving anticoagulation in Chinese Han population. The study aimed to investigate the influence of ABO blood groups on warfarin dose requirements in Chinese Han population. Methods: A retrospective study was conducted in the First Affiliated Hospital of Shantou University Medical College in Southern China. Three hundreds and 58 patients with confirmed diagnosis of deep venous thromboembolism and atrial fibrillation were included. Frequency of blood groups and warfarin dose requirements were determined. Results: Of 358 patients with deep venous thromboembolism and atrial fibrillation, 111 patients had blood group A (31.01%), 104 patinets had blood group B (29.05%), 20 patients had blood group AB (5.59%), and 123 patients had blood group O (34.36%). The patients with O blood group had a lower warfarin dose requirements compared with those with A, B and AB blood group. Conclusion: Our study showed that patients with non-O blood groups require higher doses of warfarin.


Sign in / Sign up

Export Citation Format

Share Document